A Piece Of The Puzzle Missing From Bionano Genomics, Inc.'s (NASDAQ:BNGO) 28% Share Price Climb

Bionano Genomics, Inc. (NASDAQ:BNGO) shareholders would be excited to see that the share price has had a great month, posting a 28% gain and recovering from prior weakness. But the last month did very little to improve the 85% share price decline over the last year. Even after such a large jump in price, Bionano Genomics may still be sending very bullish signals at the moment with its price-to-sales (or "P/S") ratio of 0.7x, since almost half of all companies in the Life Sciences industry in the United States have P/S ratios greater than 3.2x and even P/S higher than 7x are not unusual. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Check out our latest analysis for Bionano Genomics NasdaqCM:BNGO Price to Sales Ratio vs Industry September 14th 2025 How Has Bionano Genomics Performed Recently? Bionano Genomics hasn't been tracking well recently as its declining revenue compares poorly to other companies, which have seen some growth in their revenues on average. The P/S ratio is probably low because investors think this poor revenue performance isn't going to get any better. If you still like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour. Keen to find out how analysts think Bionano Genomics' future stacks up against the industry? In that case, our free report is a great place to start. What Are Revenue Growth Metrics Telling Us About The Low P/S? The only time you'd be truly comfortable seeing a P/S as depressed as Bionano Genomics' is when the company's growth is on track to lag the industry decidedly. Taking a look back first, the company's revenue growth last year wasn't something to get excited about as it posted a disappointing decline of 25%. That put a dampener on the good run it was having over the longer-term as its three-year revenue growth is still a noteworthy 18% in total. So we can start by confirming that the company has generally done a good job of growing revenue over that time, even though it had some hiccups along the way. Turning to the outlook, the next three years should generate growth of 29% each year as estimated by the dual analysts watching the company. That's shaping up to be materially higher than the 7.0% per year growth forecast for the broader industry. With this information, we find it odd that Bionano Genomics is trading at a P/S lower than the industry. It looks like most investors are not convinced at all that the company can achieve future growth expectations. The Final Word Shares in Bionano Genomics have risen appreciably however, its P/S is still subdued. It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator. To us, it seems Bionano Genomics currently trades on a significantly depressed P/S given its forecasted revenue growth is higher than the rest of its industry. There could be some major risk factors that are placing downward pressure on the P/S ratio. While the possibility of the share price plunging seems unlikely due to the high growth forecasted for the company, the market does appear to have some hesitation. And what about other risks? Every company has them, and we've spotted 4 warning signs for Bionano Genomics (of which 1 is a bit unpleasant!) you should know about. If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.